ExodusPoint Capital Management LP Reduces Position in Natera, Inc. (NASDAQ:NTRA)

ExodusPoint Capital Management LP lessened its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 82.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 31,471 shares of the medical research company's stock after selling 147,957 shares during the period. ExodusPoint Capital Management LP's holdings in Natera were worth $4,982,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Principal Securities Inc. raised its position in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after buying an additional 59 shares in the last quarter. Gladstone Institutional Advisory LLC increased its stake in Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock worth $574,000 after acquiring an additional 61 shares during the last quarter. Silver Oak Securities Incorporated increased its stake in Natera by 3.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock worth $470,000 after acquiring an additional 89 shares during the last quarter. Blue Trust Inc. raised its position in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares during the period. Finally, Hanseatic Management Services Inc. lifted its stake in shares of Natera by 12.0% in the 4th quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company's stock valued at $158,000 after purchasing an additional 107 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Remove Ads

Insider Buying and Selling at Natera

In related news, CFO Michael Burkes Brophy sold 25,931 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,277,837.07. Following the completion of the sale, the chief financial officer now owns 109,665 shares of the company's stock, valued at $18,091,435.05. This represents a 19.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 78,553 shares of the firm's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares of the company's stock, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 325,922 shares of company stock valued at $51,603,664. 7.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

NTRA has been the topic of several analyst reports. Morgan Stanley boosted their target price on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Barclays cut their price objective on shares of Natera from $200.00 to $160.00 and set an "overweight" rating on the stock in a research report on Thursday. Robert W. Baird raised their target price on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 price target on shares of Natera in a research note on Wednesday, February 26th. Finally, Guggenheim increased their price objective on shares of Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $175.76.

Natera Stock Up 3.3 %

Shares of NTRA stock traded up $4.76 on Friday, hitting $148.04. The stock had a trading volume of 1,364,917 shares, compared to its average volume of 1,394,665. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The business has a 50 day moving average price of $152.66 and a 200 day moving average price of $152.05. The company has a market cap of $20.01 billion, a PE ratio of -84.11 and a beta of 1.80. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.